iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Tables)

Earnings (Loss) Per Common Share (Tables)

3 Months Ended

Sep. 30, 2023

Earnings (Loss) Per Common Share [Abstract]

Schedule of Earnings (loss) Per Share, Basic and Diluted


		Three Months Ended
		September 30,
		2023			2022
Basic and diluted numerator:

Net loss available to iBio, Inc. stockholders from continuing operations		$	(5,074)		$	(7,537)

Net loss available to iBio, Inc. stockholders from discontinued operations		$	(672)		$	(10,593)

Net loss available to iBio, Inc. stockholders - total		$	(5,746)		$	(18,130)

Basic and diluted denominator:

Weighted-average common shares outstanding			23,969			8,842

Per share amount - continuing operations		$	(0.21)		$	(0.85)
Per share amount - discontinued operations		$	(0.03)		$	(1.20)
Per share amount - total		$	(0.24)		$	(2.05)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share


		September 30,
		2023		2022

		(in thousands)
Stock options		765		923
Restricted stock units		158		27
Warrants		5,871		51
Shares excluded from the calculation of diluted loss per share		6,794		1,001